CN105263922B - 三唑化合物及其作为γ分泌酶调节剂的用途 - Google Patents

三唑化合物及其作为γ分泌酶调节剂的用途 Download PDF

Info

Publication number
CN105263922B
CN105263922B CN201480031629.0A CN201480031629A CN105263922B CN 105263922 B CN105263922 B CN 105263922B CN 201480031629 A CN201480031629 A CN 201480031629A CN 105263922 B CN105263922 B CN 105263922B
Authority
CN
China
Prior art keywords
relevant
pharmaceutically acceptable
compound
disease
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201480031629.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN105263922A (zh
Inventor
Y.贝西德斯基
U.英格夫
K.保尔森
C.林德
J.马姆博格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acturum Life Science AB
Original Assignee
Acturum Life Science AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acturum Life Science AB filed Critical Acturum Life Science AB
Publication of CN105263922A publication Critical patent/CN105263922A/zh
Application granted granted Critical
Publication of CN105263922B publication Critical patent/CN105263922B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201480031629.0A 2013-06-04 2014-06-03 三唑化合物及其作为γ分泌酶调节剂的用途 Expired - Fee Related CN105263922B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1350684-5 2013-06-04
SE1350684 2013-06-04
PCT/EP2014/061501 WO2014195322A1 (en) 2013-06-04 2014-06-03 Triazole compounds and their use as gamma secretase modulators

Publications (2)

Publication Number Publication Date
CN105263922A CN105263922A (zh) 2016-01-20
CN105263922B true CN105263922B (zh) 2018-08-17

Family

ID=50896282

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480031629.0A Expired - Fee Related CN105263922B (zh) 2013-06-04 2014-06-03 三唑化合物及其作为γ分泌酶调节剂的用途

Country Status (7)

Country Link
US (1) US9718805B2 (2)
EP (1) EP3004080B1 (2)
JP (1) JP6396438B2 (2)
CN (1) CN105263922B (2)
DK (1) DK3004080T3 (2)
ES (1) ES2701810T3 (2)
WO (1) WO2014195322A1 (2)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6887952B2 (ja) 2015-02-25 2021-06-16 プリレニア ニューロセラピューティクス リミテッド 認知機能を改善するため、およびアルツハイマー病を治療するためのプリドピジンの使用
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
US10576125B2 (en) 2016-10-31 2020-03-03 Hough Ear Institute Methods for enhancing synaptogenesis and neuritogenesis
AU2018281330A1 (en) * 2017-06-05 2019-12-19 Case Western Reserve University Compositions and methods for treating alzheimer's disease
CN121202886A (zh) * 2024-06-26 2025-12-26 浙江养生堂天然药物研究所有限公司 杂环类化合物及其用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009032277A1 (en) * 2007-09-06 2009-03-12 Schering Corporation Gamma secretase modulators
WO2009103652A1 (en) * 2008-02-22 2009-08-27 F. Hoffmann-La Roche Ag Modulators for amyloid beta
CN102762561A (zh) * 2010-02-01 2012-10-31 霍夫曼-拉罗奇有限公司 γ分泌酶调节物
CN102906083A (zh) * 2010-01-15 2013-01-30 杨森制药公司 作为γ分泌酶调节剂的新的取代的三唑衍生物

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20030312A1 (it) 2003-02-21 2004-08-22 Chiesi Farma Spa Derivati di acidi 2-fenil-2-alchil-acetici per il trattamento della malattia di alzheimer.
AU2004262970B2 (en) 2003-08-07 2010-03-18 Merck Sharp & Dohme Limited Treatment for Alzheimer's disease and related conditions
JP2007513128A (ja) 2003-12-03 2007-05-24 メルク　エンド　カムパニー　インコーポレーテッド アルツハイマー病および関連状態の治療に有用な１−アルキル−３−チオ置換インドール−２−アルキン酸
RU2361872C2 (ru) 2004-05-26 2009-07-20 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Циннамидное соединение
WO2007125364A1 (en) 2006-04-26 2007-11-08 Merck Sharp & Dohme Limited Piperidines and related compounds for treatment of alzheimer’s disease
JPWO2007135969A1 (ja) 2006-05-19 2009-10-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 ウレア系−シンナミド誘導体
JP2009184924A (ja) 2006-05-31 2009-08-20 Eisai R & D Management Co Ltd 生物学的試薬用化合物
JP2010518080A (ja) 2007-02-08 2010-05-27 メルク・シャープ・エンド・ドーム・コーポレイション 治療薬
US8252803B2 (en) 2007-02-12 2012-08-28 Merck Sharp & Dohme Corp. Piperidine derivatives
CA2676715A1 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
EP2166854A4 (en) 2007-06-13 2012-05-16 Merck Sharp & Dohme TRIAZONE DERIVATIVES FOR THE TREATMENT OF MORBUS ALZHEIMER AND RELATED SUFFERINGS
CA2695543A1 (en) 2007-08-06 2009-02-12 Schering Corporation Gamma secretase modulators
WO2009087127A1 (en) 2008-01-11 2009-07-16 F. Hoffmann-La Roche Ag Modulators for amyloid beta
MX2011004680A (es) 2008-11-06 2011-05-25 Astrazeneca Ab Moduladores de beta amiloide.
AU2009312856A1 (en) 2008-11-10 2010-05-14 F. Hoffmann-La Roche Ag Heterocyclic gamma secretase modulators
TW201030002A (en) 2009-01-16 2010-08-16 Bristol Myers Squibb Co Bicyclic compounds for the reduction of beta-amyloid production
UY32622A (es) 2009-05-12 2010-12-31 Astrazeneca Ab Nuevos compuestos para el tratamiento de patologías relacionadas con ab(beta)
ES2519565T3 (es) * 2009-07-15 2014-11-07 Janssen Pharmaceuticals Inc. Derivados de triazol e imidazol sustituidos como moduladores de gamma secretasa
TWI468402B (zh) 2009-07-31 2015-01-11 必治妥美雅史谷比公司 降低β－類澱粉生成之化合物
TW201206946A (en) 2010-07-15 2012-02-16 Bristol Myers Squibb Co Compounds for the reduction of beta-amyloid production

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009032277A1 (en) * 2007-09-06 2009-03-12 Schering Corporation Gamma secretase modulators
WO2009103652A1 (en) * 2008-02-22 2009-08-27 F. Hoffmann-La Roche Ag Modulators for amyloid beta
CN102906083A (zh) * 2010-01-15 2013-01-30 杨森制药公司 作为γ分泌酶调节剂的新的取代的三唑衍生物
CN102762561A (zh) * 2010-02-01 2012-10-31 霍夫曼-拉罗奇有限公司 γ分泌酶调节物

Also Published As

Publication number Publication date
WO2014195322A1 (en) 2014-12-11
EP3004080B1 (en) 2018-10-10
US9718805B2 (en) 2017-08-01
CN105263922A (zh) 2016-01-20
JP2016520636A (ja) 2016-07-14
US20160108022A1 (en) 2016-04-21
DK3004080T3 (da) 2019-01-02
ES2701810T3 (es) 2019-02-26
JP6396438B2 (ja) 2018-09-26
EP3004080A1 (en) 2016-04-13

Similar Documents

Publication Publication Date Title
CN114671864B (zh) 杂芳基取代的吡啶及使用方法
EP3022202B1 (en) Autotaxin inhibitors comprising a heteroaromatic ring-benzyl-amide-cycle core
CN105308037B (zh) 三唑化合物及其作为γ分泌酶调节剂的用途
JP7033079B2 (ja) 芳香族スルホンアミド誘導体
CN107787323B (zh) 用于抑制shp2活性的化合物和组合物
JP5621148B2 (ja) ５−ｈｔ２ｂ受容体拮抗活性を有する新規ピラゾール−３−カルボキサミド誘導体
CN105263922B (zh) 三唑化合物及其作为γ分泌酶调节剂的用途
JP2007534740A (ja) バソプレッシンＶ１ａ受容体の阻害剤としての３−ヘテロシクリル−４−フェニル−トリアゾール誘導体
CN120957993A (zh) 杂环glp-1激动剂
PT2060570E (pt) Derivados de azabiciclo(3.1.0)-hexano úteis como moduladores dos receptores d3 da dopamina
CN105263923B (zh) 嘧啶化合物及它们作为γ分泌酶调节剂的用途
JP2013519716A (ja) ５−ｈｔ受容体モジュレーター
JP2008533193A (ja) オキシトシン拮抗薬としての置換トリアゾール誘導体
AU2015316472B2 (en) N-(hetero)aryl-substituted heteroyclic derivatives useful for the treatment of diseases or conditions related to the central nervous system
JP2016522244A (ja) プロキネシチン受容体のモジュレータとしての１−スルホニルピペリジン誘導体
CN107074777A (zh) 苄基醇衍生物、其制备方法及其治疗用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20180817